High blood pressure (arterial hypertension) affects an estimated 30–45% of all adults and is one of the most important risk factors for heart attack, stroke and kidney disease. That diet and certain nutrients can influence blood pressure is well documented — the DASH diet and salt reduction are prominent examples. Omega-3 fatty acids (EPA and DHA) have also been in the focus of blood pressure research for decades. The EFSA has even approved an official health claim for EPA+DHA in normal blood pressure — but only from a considerably higher dose than for the cardiac function claim. What is behind these figures, and what do the studies really say? This article provides a comprehensive, scientifically grounded overview.
The EFSA health claim: normal blood pressure
The European Food Safety Authority (EFSA) has approved the following health claim for EPA and DHA: EPA and DHA contribute to the maintenance of normal blood pressure. Unlike the cardiac function claim (250 mg/day), this claim only applies from a minimum dose of 3,000 mg (3 g) EPA+DHA per day. This is a considerable amount — corresponding to a larger supplementation dose that is barely achievable through normal diet.
EFSA Health Claim: blood pressure
According to the EFSA, EPA and DHA contribute to the maintenance of normal blood pressure. Approved minimum dose: 3,000 mg EPA+DHA per day. Foods or dietary supplements may only carry this claim if they contain at least 3 g EPA+DHA per daily serving. (EU Regulation No. 432/2012)
The high dosage requirement of 3 g/day reflects that blood pressure-lowering effects have been demonstrated consistently in studies primarily at higher doses and especially in people with already elevated blood pressure. In normotensive people, effects are generally small.
The key study: Miller et al. — meta-analysis of 70 RCTs
The most comprehensive and widely cited analysis on omega-3 and blood pressure comes from Miller, Van Elswyk and Alexander (2014), published in the American Journal of Hypertension. The authors analysed 70 randomised controlled trials (RCTs) — one of the largest summaries on this topic at the time.
Results: systolic and diastolic
In the total population of all 70 RCTs, omega-3 supplementation showed:
- Systolic blood pressure: −1.52 mmHg (statistically significant)
- Diastolic blood pressure: −0.99 mmHg (statistically significant)
These figures sound small — and they are, on average. However, the subgroup analyses are decisive.
Stronger effects in people with hypertension
Particularly informative: in people with untreated high blood pressure (hypertension), considerably stronger effects were seen:
- Systolic: −4.51 mmHg
- Diastolic: −3.05 mmHg
Clinically, this magnitude is relevant: a reduction in systolic blood pressure of 5 mmHg at population level is associated with a reduction in stroke risk of approximately 14% and ischaemic heart disease risk of approximately 9% (according to epidemiological data). Omega-3 alone achieves this reduction — but in combination with other lifestyle measures (salt reduction, physical activity, weight loss), such effects add up.
Blood pressure reduction with omega-3: analysis of 70 randomised trials
The meta-analysis of 70 RCTs showed a significant reduction in systolic blood pressure of −1.52 mmHg (95% CI −2.10 to −0.94) and diastolic −0.99 mmHg (95% CI −1.54 to −0.44) in the total population. In patients with untreated hypertension: systolic −4.51 mmHg, diastolic −3.05 mmHg. Higher doses and higher baseline blood pressure levels were associated with stronger effects.
Mechanisms: how can omega-3 influence blood pressure?
Several physiological mechanisms are discussed for the blood pressure-relevant effects of EPA and DHA:
Endothelial function and nitric oxide
EPA and DHA can increase the release of nitric oxide (NO) from endothelial cells. NO acts as a vasodilator — it relaxes the smooth muscle of blood vessel walls and thereby reduces peripheral vascular resistance. Improved endothelial function is a central protective mechanism against hypertension and arteriosclerosis.
Reduced synthesis of vasoconstrictive eicosanoids
Omega-3 fatty acids compete in cell membranes with arachidonic acid (omega-6) for the same enzymes (cyclooxygenase, lipoxygenase). When EPA and DHA are present, fewer vasoconstrictive prostaglandins (e.g. thromboxane A2) and more vasodilatory eicosanoids are formed. This shifts the balance towards lower vascular tension.
Reduction in heart rate
Some studies show that EPA and DHA can slightly lower heart rate. A lower heart rate means a lower cardiac output with the same stroke volume — a further blood pressure-relevant mechanism.
Inflammation modulation
Chronic inflammatory processes in the vascular wall contribute to the development of hypertension. EPA and DHA consistently reduce inflammatory markers CRP, IL-6 and TNF-alpha in meta-analyses. They can thereby indirectly dampen vascular inflammatory processes that elevate blood pressure.
What dosage is relevant in high blood pressure?
| Dosage EPA+DHA/day | Expected blood pressure effect | Target group per study evidence |
|---|---|---|
| < 1,000 mg | Barely measurable | General population (basic supply) |
| 1,000–2,000 mg | Small to moderate in people with hypertension | Preventive, elevated risk |
| 2,000–3,000 mg | Moderate (also EFSA triglyceride claim) | Hypertension + hypertriglyceridaemia |
| 3,000 mg (EFSA claim) | Demonstrated: normal blood pressure regulation | Hypertension — after medical assessment |
| > 3,000 mg | Stronger, but higher interaction risk | Only under medical supervision |
Important: omega-3 fatty acids do not replace antihypertensive medications. They can be used as part of a comprehensive lifestyle approach, but should always be done in consultation with a doctor — especially if blood pressure-lowering medications are already being taken.
Omega-3 in context: what else acts on blood pressure?
For a realistic comparison: how large is the blood pressure-lowering effect of omega-3 compared to other lifestyle measures?
- Salt reduction (to < 5 g/day): approx. −4 to −5 mmHg
- DASH diet: approx. −6 mmHg
- Regular aerobic exercise (5x/week): approx. −5 mmHg
- Weight loss (−5 kg): approx. −4 mmHg
- Omega-3 (3 g/day, hypertension subgroup): approx. −4.5 mmHg
- Alcohol reduction: approx. −3 mmHg
Omega-3 in people with hypertension and at higher doses is therefore quite comparable in magnitude with other recognised non-pharmacological measures. Combined, an additive effect results.
Frequently asked questions
How much can omega-3 lower blood pressure?
According to the meta-analysis by Miller et al. (70 RCTs), omega-3 lowers systolic blood pressure in the general population by an average of −1.52 mmHg. In people with hypertension the effect was considerably stronger: −4.51 mmHg systolic. The effect is therefore moderate but clinically relevant — especially in high-risk individuals and in combination with other lifestyle measures.
When does the blood pressure-lowering effect set in?
Studies show measurable blood pressure effects after 4–12 weeks of regular supplementation. Short-term intake over a few days is not sufficient. For a stable effect, studies recommend continuous intake over several months. The omega-3 index stabilises at a new level after approximately 8–12 weeks.
Is 1 g of omega-3 per day enough for blood pressure?
No. The EFSA health claim for normal blood pressure regulation only applies from 3 g EPA+DHA per day. At 1 g/day, blood pressure-lowering effects are usually not significantly demonstrable in studies. For the general cardiovascular health claim (normal cardiac function), 250 mg/day is sufficient — but not for the blood pressure claim.
Does omega-3 also work preventively against high blood pressure?
The evidence for a primary preventive effect in people with normal blood pressure is weaker. In the Miller et al. meta-analysis, effects in the normotensive subgroup were small. Omega-3 appears to be most effective when elevated baseline values already exist. For general cardiovascular prevention, regular fish consumption or supplementation in the range of 250–500 mg/day is recommended.
Can omega-3 replace blood pressure medications?
No. Omega-3 can be a useful complement to a lifestyle concept in hypertension, but it does not replace medically prescribed antihypertensives. Untreated high blood pressure is a dangerous risk factor for stroke and heart attack. The decision to reduce or stop blood pressure medications must always be discussed with a doctor.
Related articles
High blood pressure is often associated with further cardiovascular risk factors that are also influenced by omega-3:
- Omega-3 and heart health — EFSA health claim, REDUCE-IT trial and meta-analyses with 127,477 participants
- Lowering triglycerides with omega-3 — AHA Science Advisory and EFSA health claim from 2,000 mg/day
Self-treatment of high blood pressure is not an option
High blood pressure is a medical condition that must be diagnosed and treated. Omega-3 fatty acids can be a nutritional supplement within a comprehensive treatment concept — they do not replace blood pressure measurement, medical diagnosis or medically prescribed medications. Please speak with your doctor before using high-dose omega-3 supplements for blood pressure control.
Medical disclaimer
This article is for general informational purposes and does not replace medical advice. All health claims are based on EFSA-approved health claims and published studies. High blood pressure is a serious condition requiring medical diagnosis and treatment. Dietary supplements are not a substitute for a balanced diet, exercise or medically prescribed medications.